01—Abstract
Summary
Summary of the 8-K filed July 24, 2025. Cited figures are marked; the original filing is the authoritative source.
West Pharmaceutical Services, Inc. (NYSE: WST) reported second-quarter 2025 results on July 24, 2025, per Exhibit 99.1, a press release that also announced a fourth-quarter 2025 dividend of $0.22a per share, payable November 19, 2025 to holders of record as of November 12, 2025.
Net sales were $766.5 millionb, up 9.2%, with organic net sales growth of 6.8%. Diluted EPS was $1.82 versus $1.51 a year earlier, and adjusted-diluted EPS was $1.84 versus $1.52. High-Value Product (HVP) Components grew 11.3% and were 47% of total company net sales, while the Contract-Manufactured Products segment rose 3.0% to $146.7 million.
The company raised its full-year 2025 guidance. Net sales guidance moved to $3.040 billion to $3.060 billionc from $2.945 billion to $2.975 billion, with organic growth now expected at approximately 3% to 3.75% versus the prior 2% to 3%. Adjusted-diluted EPS guidance rose to $6.65 to $6.85 from $6.15 to $6.35.
Management attributed the increase to strong second-quarter performance and favorable foreign exchange, which the filing says is a $59 milliond net sales tailwind and a $0.27 adjusted EPS tailwind. Guidance also incorporates an estimated $15 to $20 million net impact from recently implemented tariffs. Full-year capital spending guidance is unchanged at $275 million.
For the first six months of 2025, operating cash flow was $306.5 million, up 8.2%, and capital expenditures were $146.5 million, down 23.2%, producing free cash flow of $160.0 million versus $92.4 million a year earlier. The company repurchased 552,593 shares for $134.0 million during the period. Cash and cash equivalents were $509.7 million and debt was $202.6 million as of June 30, 2025.
02—Key points
Key Highlights
- Q2 2025 net sales of $766.5 million, up 9.2%; organic net sales growth of 6.8%
- Diluted EPS of $1.82 vs. $1.51 prior year; adjusted-diluted EPS of $1.84 vs. $1.52
- Full-year 2025 net sales guidance raised to $3.040–$3.060 billion from $2.945–$2.975 billion
- Full-year 2025 adjusted-diluted EPS guidance raised to $6.65–$6.85 from $6.15–$6.35
- HVP Components grew 11.3% and represented 47% of total net sales; HVP Delivery Devices grew 30.0%
- Six-month free cash flow of $160.0 million vs. $92.4 million, with operating cash flow of $306.5 million
- Quarterly dividend of $0.22 per share declared for Q4 2025, payable November 19, 2025
03—Questions
Frequently Asked Questions
Why did West raise its full-year 2025 guidance?
Management said strong second-quarter performance and favorable foreign exchange drove the increase. Growth in HVP components, including strong GLP-1 elastomer sales, ongoing HVP conversion related mainly to Annex 1 projects, and normalizing customer ordering patterns contributed. The company also noted that the improved performance was concentrated in higher-margin products.
How much of the guidance increase is due to currency?
The filing states that net sales guidance includes an estimated full-year 2025 tailwind of approximately $59 million from current foreign exchange rates, compared with a previous headwind of approximately $5 million. Adjusted-diluted EPS guidance assumes a $0.27 foreign exchange tailwind, compared with no impact previously.
What are the expected tariff costs?
Updated adjusted-diluted EPS guidance incorporates management's estimate of $15 to $20 million for the net impact of recently implemented tariffs. The prior estimate in the presentation was $20 million to $25 million.
What is the dividend and when is it paid?
The Board of Directors approved a fourth-quarter 2025 dividend of $0.22 per share. It will be paid on November 19, 2025, to shareholders of record as of November 12, 2025.
How did the segments perform?
The Proprietary Products segment grew 10.7% to $619.8 million, with organic growth of 8.4%. The Contract-Manufactured Products segment rose 3.0% to $146.7 million, or 0.5% on an organic basis, driven by self-injection devices for obesity and diabetes, partially offset by lower healthcare diagnostic device sales.
04—Continue